Neuroendocrine tumor therapy

177Lu-DOTATATE

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE. The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of 177Lu-tetraazacyclododecanetetraacetic acid–octreotide (177Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs. CONCLUSION. In January 2018, 177Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut. The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures. Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences. Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity. A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalAmerican Journal of Roentgenology
Volume211
Issue number2
DOIs
StatePublished - Aug 1 2018

Fingerprint

Neuroendocrine Tumors
Peptide Receptors
Therapeutics
Radioisotopes
(177lutetium-DOTA(O)Tyr3)octreotate
Somatostatin
Patient Selection
Disease-Free Survival
Quality of Life
Clinical Trials
Survival

Keywords

  • Lu
  • DOTATATE
  • NETTER-1 trial
  • Neuroendocrine tumors
  • Peptide receptor radionuclide therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Neuroendocrine tumor therapy : 177Lu-DOTATATE. / Mittra, Erik.

In: American Journal of Roentgenology, Vol. 211, No. 2, 01.08.2018, p. 278-285.

Research output: Contribution to journalArticle

@article{a4e7a61b75a442829a224eb0fd7d0f44,
title = "Neuroendocrine tumor therapy: 177Lu-DOTATATE",
abstract = "OBJECTIVE. The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of 177Lu-tetraazacyclododecanetetraacetic acid–octreotide (177Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs. CONCLUSION. In January 2018, 177Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut. The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures. Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences. Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity. A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.",
keywords = "Lu, DOTATATE, NETTER-1 trial, Neuroendocrine tumors, Peptide receptor radionuclide therapy",
author = "Erik Mittra",
year = "2018",
month = "8",
day = "1",
doi = "10.2214/AJR.18.19953",
language = "English (US)",
volume = "211",
pages = "278--285",
journal = "AJR. American journal of roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

TY - JOUR

T1 - Neuroendocrine tumor therapy

T2 - 177Lu-DOTATATE

AU - Mittra, Erik

PY - 2018/8/1

Y1 - 2018/8/1

N2 - OBJECTIVE. The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of 177Lu-tetraazacyclododecanetetraacetic acid–octreotide (177Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs. CONCLUSION. In January 2018, 177Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut. The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures. Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences. Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity. A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.

AB - OBJECTIVE. The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of 177Lu-tetraazacyclododecanetetraacetic acid–octreotide (177Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs. CONCLUSION. In January 2018, 177Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut. The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures. Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences. Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity. A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.

KW - Lu

KW - DOTATATE

KW - NETTER-1 trial

KW - Neuroendocrine tumors

KW - Peptide receptor radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=85052395517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052395517&partnerID=8YFLogxK

U2 - 10.2214/AJR.18.19953

DO - 10.2214/AJR.18.19953

M3 - Article

VL - 211

SP - 278

EP - 285

JO - AJR. American journal of roentgenology

JF - AJR. American journal of roentgenology

SN - 0361-803X

IS - 2

ER -